Abnormalities in the Lipid and lipoprotein levels are common in the general population and are considered as very important risk- factors for cardiovascular disease .In this context the effect of cholesterol, which is one of the most clinically relevant lipids is very important. Aim of the present study was to determine the levels of GLP-1 and GPCR in non- diabetic dyslipidaemic patients and compare the results with the control group, which may be used as a novel biomarker to predict heart disease in these patients. The study was also aimed to find the relationship between GLP-1 and GPCR with lipid profile and glucagon in the patient group. The study involved 90 non-diabetic dyslipidaemia patients, with 90 healthy controls. The subjects were matched by age (35-50 years) and body mass index (BMI) (28 kg/m2). Blood samples were collected from healthy controls and dyslipidaemic patients after 12-14 hours of fasting. The study was conducted between January 2015– September 2015 in the Ibn- Al Naphes hospital in Baghdad province / Iraq .Diabetic patients were exclusion from this study. BMI were determined for all student groups.FBG, Lipid Profile ,glucagon, GLP-1, GPCR was determined in the control and patient groups. The results are expressed as mean ± SEM. Student ̓s t-test was used to compare the significance of the variation between dyslipidaemia and control groups. Results showed nonsignificant elevations in BMI, FBS, and HbA1c levels in the patient group compared with the control group. There was a significant elevation in TC, TG, LDL-c, and VLDL-c levels in the patient group compared with the control group, while a significant decrease was noticed in HDL-c level in the patient group compared with the control group .There was also a significant elevation in glucagon, while a highly significant elevation in GLP-1 and GPCR levels in the patient group when compared with the control group. A significant correlation was observed between GLP-1 with TC, TG, HDL-c, and GPCR in the patient group. There was also a significant correlation between GPCR with TC, TG and HDL-c in the patient group. From this study, it is concluded that a significant increase in GLP-1and GPCR levels, in addition to their correlation with TC, TG, HDL-c and glucagon in the patient group, compared to the control group indicate that these parameters could be used as a novel biomarker to predict heart disease in these patients in future.
GLP-1, GPCR Levels and their Relationshipwith Some Parameters in Nondiabetic Dyslipidaemia in Iraqi Patients
GLP-1
GPCR
non-diabetic dyslipidaemia patients.
Publication Date
Sat Dec 01 2012
Journal Name
Advances In Bioresearch
Cytotoxicity of Miltefosine against Leishmania majorPromastigotes
Leishmaniasis has poor vaccination trials and the available drugs have side effects on patients. Therefore
development ofnew chemicals is important for public health. Miltefosine is the first drug used for oral treatment of visceral leishmaniasis.Previous studies approved that miltefosine is an effective treatment against visceral leishmaniasis
the visceral form ofLeishmania
and also on L. major
the cutaneous form of Leishmania. Here
we investigated the in vitro cytotoxicity ofmiltefosine on the procyclic promastigotes forms of L. major. Different concentrations of miltefosine were investigatedagainst the flagellated form of L. major
and results showed that miltefosine has inhibited the in vitro proliferation of theparasite
approving the cytotoxic effect of the compound on Leishmania
EC50 was determined after 24 hours exposure forthe drug and it was 1.54 μM. Our findings indicate that miltefosine has a cytotoxic effect on the insect stage of the old worldL. major and can be a new anti-Leishmanial drug